Rafael Holdings, Inc. (NYSE: RFL)
Health Care · Pharmaceuticals · US
$2.28
+5.56% today · +46.9% 1Y
Rafael Holdings, Inc. (NYSE: RFL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $112.32M and employs 22 people.
Over the last twelve months the share price has gained 46.9%, trading between 1.12 and 3.96.
Tweenvest scores Rafael Holdings, Inc. across four factors: quality 36/100, value 55/100, growth 8/100. Its strongest factor is value.
RFL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $112.32M
- Revenue (TTM)
- $980.00K
- P/E
- —
- EPS
- -0.67
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- $3.96
- 52-week low
- $1.12
- Avg volume (3M)
- —
- Shares outstanding
- 52.00M
- Employees
- 22
- Next earnings
- —
About Rafael Holdings, Inc.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
- ISIN
- US75062E1064
- Founded
- 2017
- Listed since
- Mar 27, 2018
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.82 | +0.07% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.26 | +0.08% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.29 | +3.74% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.41 | +1.56% |
Figures last refreshed Aug 18, 2026.